GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (OTCPK:SLNCF) » Definitions » Days Sales Outstanding

Silence Therapeutics (Silence Therapeutics) Days Sales Outstanding : 14.78 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Silence Therapeutics Days Sales Outstanding?

Silence Therapeutics's average Accounts Receivable for the three months ended in Dec. 2023 was $0.43 Mil. Silence Therapeutics's Revenue for the three months ended in Dec. 2023 was $2.66 Mil. Hence, Silence Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 14.78.

The historical rank and industry rank for Silence Therapeutics's Days Sales Outstanding or its related term are showing as below:

SLNCF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.7   Med: 383.99   Max: 17572.14
Current: 45.52

During the past 13 years, Silence Therapeutics's highest Days Sales Outstanding was 17572.14. The lowest was 5.70. And the median was 383.99.

SLNCF's Days Sales Outstanding is ranked better than
73.09% of 892 companies
in the Biotechnology industry
Industry Median: 72.29 vs SLNCF: 45.52

Silence Therapeutics's Days Sales Outstanding increased from Dec. 2022 (9.91) to Dec. 2023 (14.78).


Silence Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Silence Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Days Sales Outstanding Chart

Silence Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.70 976.32 440.30 13.30 7.97

Silence Therapeutics Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.91 10.47 69.91 212.53 14.78

Competitive Comparison of Silence Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Silence Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silence Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Days Sales Outstanding falls into.



Silence Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Silence Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (1.114 + 0.289) / 2 ) / 32.12*365
=0.7015 / 32.12*365
=7.97

Silence Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (0.572 + 0.289) / 2 ) / 2.657*365 / 4
=0.4305 / 2.657*365 / 4
=14.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Silence Therapeutics  (OTCPK:SLNCF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Silence Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Silence Therapeutics (Silence Therapeutics) Business Description

Traded in Other Exchanges
Address
72 Hammersmith Road, London, GBR, W14 8TH
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.